Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints-Reference-Cited by-同舟云学术

Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints

Published:2010-05 Issue:10 Volume:79 Page:1387-1397
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Sabisz Michal,Węsierska-Gądek Józefa,Skladanowski Andrzej

Funder

Polish Ministry of Science and Higher Education

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference41 articles.

1. Poly(ADP-ribose) in the cellular response to DNA damage;Berger;Radiat Res,1988

2. Poly(ADP-ribose) polymerase: a molecular nick-sensor;de Murcia;Trends Biochem Sci,1994

3. Involvement of poly(ADP-ribose) polymerase in base excision repair;Dantzer;Biochimie,1999

4. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents;Bryant;Biochem Soc Trans,2004

5. Chemopotentiation by PARP inhibitors in cancer therapy;Tentori;Pharm Res,2005

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis;Journal of Cellular and Molecular Medicine;2022-06-14

2. Dual targeting, a new strategy for novel PARP inhibitor discovery;Drug Discoveries & Therapeutics;2021-12-31

3. Triazoloacridone C-1305 impairs XBP1 splicing by acting as a potential IRE1α endoribonuclease inhibitor;Cellular & Molecular Biology Letters;2021-03-17

4. Polyploidy formation in cancer cells: How a Trojan horse is born;Seminars in Cancer Biology;2021-03

5. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma;International Immunopharmacology;2020-12